Compare IBIO & APT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBIO | APT |
|---|---|---|
| Founded | 2008 | 1983 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.0M | 59.6M |
| IPO Year | 2009 | 1997 |
| Metric | IBIO | APT |
|---|---|---|
| Price | $0.76 | $5.68 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $5.69 | N/A |
| AVG Volume (30 Days) | ★ 858.9K | 66.9K |
| Earning Date | 11-11-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 81.71 | N/A |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $59,142,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $23.83 |
| Revenue Growth | N/A | ★ 2.25 |
| 52 Week Low | $0.73 | $4.34 |
| 52 Week High | $3.82 | $7.50 |
| Indicator | IBIO | APT |
|---|---|---|
| Relative Strength Index (RSI) | 19.34 | 53.20 |
| Support Level | N/A | $5.46 |
| Resistance Level | $1.52 | $6.20 |
| Average True Range (ATR) | 0.08 | 0.28 |
| MACD | -0.03 | 0.01 |
| Stochastic Oscillator | 6.77 | 46.49 |
iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.
Alpha Pro Tech Ltd is in the business of protecting people, products, and environments. It is developing, manufacturing, and marketing a line of disposable protective apparel and infection control products for the cleanroom, industrial, pharmaceutical, medical, and dental markets. It also manufactures a line of building supply construction weatherization products that are sold under the Alpha Pro Tech brand name. The Company operates through two business segments: Building Supply and Disposable Protective Apparel. Key revenue is generated from Building Supply, consisting of a line of construction supply weatherization products. The construction supply weatherization products consist of housewrap and synthetic roof underlayment, and synthetic roof underlayment accessories.